Equities research analysts expect that Acer Therapeutics Inc (NASDAQ:ACER) will report ($0.56) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Acer Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.50) and the lowest estimate coming in at ($0.62). Acer Therapeutics reported earnings of ($1.04) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 46.2%. The firm is expected to announce its next earnings report on Tuesday, March 27th.
On average, analysts expect that Acer Therapeutics will report full year earnings of ($1.64) per share for the current fiscal year, with EPS estimates ranging from ($1.80) to ($1.48). For the next year, analysts anticipate that the firm will post earnings of ($2.90) per share, with EPS estimates ranging from ($3.35) to ($2.59). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Acer Therapeutics.
A number of equities research analysts have recently weighed in on the company. ValuEngine lowered Acer Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. William Blair assumed coverage on Acer Therapeutics in a research note on Friday, February 16th. They set an “outperform” rating on the stock. Roth Capital assumed coverage on Acer Therapeutics in a research note on Monday. They set a “buy” rating and a $70.00 price target on the stock. Finally, HC Wainwright set a $50.00 price target on Acer Therapeutics and gave the stock a “buy” rating in a research note on Thursday, January 4th.
A number of hedge funds and other institutional investors have recently modified their holdings of ACER. Ardsley Advisory Partners purchased a new stake in Acer Therapeutics in the fourth quarter valued at approximately $212,000. Stonepine Capital Management LLC purchased a new stake in Acer Therapeutics in the fourth quarter valued at approximately $1,385,000. J. Goldman & Co LP purchased a new stake in Acer Therapeutics in the fourth quarter valued at approximately $1,496,000. Finally, Perceptive Advisors LLC purchased a new stake in Acer Therapeutics in the fourth quarter valued at approximately $2,091,000. Hedge funds and other institutional investors own 1.52% of the company’s stock.
Acer Therapeutics Company Profile
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.